Impact of raloxifene or tamoxifen use on endometrial cancer risk: A population-based case-control study

Journal of Clinical Oncology

Volumn 26, Issue 25, 2008, Pages 4151-4159

  DeMichele, Angela ^a   Troxel, Andrea B ^a   Berlin, Jesse A ^a   Weber, Anita L ^a   Bunin, Greta R ^a   Turzo, Elene ^a   Schinnar, Rita ^a   Burgh, Desiree ^a   Berlin, Michelle ^a   Rubin, Stephen C ^a   Rebbeck, Timothy R ^a   Strom, Brian L ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RALOXIFENE; TAMOXIFEN;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; ENDOMETRIUM CANCER; EUROPEAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

AGED; ANTICARCINOGENIC AGENTS; CASE-CONTROL STUDIES; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; ODDS RATIO; QUESTIONNAIRES; RALOXIFENE; RISK; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 51649084822     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.0921     Document Type: Article

References (24)

1. Ries L, Eisner M, Kosary C, et al: SEER Cancer Statistics Review, 1973-1997. Bethesda, MD, National Cancer Institute, 2000
2. Fornander T, Rutqvist LE, Cedermark B, et al: Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1:117-120, 1989
3. Shang Y, Brown M: Molecular determinants for the tissue specificity of SERMs. Science 295:2465-2468, 2002
4. Barsalou A, Dayan G, Anghel SI, et al: Growthstimulatory and transcriptional activation properties of raloxifene in human endometrial Ishikawa cells. Mol Cell Endocrinol 190:65-73, 2002
5. Cummings SR, Eckert S, Krueger KA, et al: The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial - Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197, 1999
6. Martino S, Cauley JA, Barrett-Connor E, et al: Continuing outcomes relevant to Evista: Breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 96:1751-1761, 2004
7. Ettinger B, Black DM, Mitlak BH, et al: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial - Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645, 1999
8. Zhang H, McElrath T, Tong W, et al: The molecular basis of tamoxifen induction of mouse uterine epithelial cell proliferation. J Endocrinol 184:129-140, 2005
9. Kleinman D, Karas M, Danilenko M, et al: Stimulation of endometrial cancer cell growth by tamoxifen is associated with increased insulin-like growth factor (IGF)-I induced tyrosine phosphorylation and reduction in IGF binding proteins. Endocrinology 137:1089-1095, 1996
10. Vogel VG, Costantino JP, Wickerham DL, et al: Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2727-2741, 2006
11. Bunin GR, Baumgarten M, Norman SA, et al: Practical aspects of sharing controls between case-control studies. Pharmacoepidemiol Drug Saf 14:523-530, 2005
12. Kleinbaum D, Kupper L, Morgenstern H: Epideiologic Research, Principles and Quantitative Methods. Belmont, CA, Lifetime Learning Publications, 1982
13. Maldonado G, Greenland S: Simulation study of confounder-selection strategies. Am J Epidemiol 138:923-936, 1993
14. Mickey RM, Greenland S: The impact of confounder selection criteria on effect estimation. Am J Epidemiol 129:125-137, 1989
15. National Surgical Adjuvant Breast and Bowel Project: Initial results of the study of tamoxifen and raloxifene (STAR) release: Osteoporosis drug raloxifene shown to be as effective as tamoxifen in preventing invasive breast cancer. Pittsburgh, PA, NSABP Operations Center, 2006
16. Fisher B, Costantino JP, Redmond CK, et al: Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527-537, 1994
17. van Leeuwen FE, Benraadt J, Coebergh JW, et al: Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448-452, 1994
18. Rydén S, Ferno M, Moller T, et al: Long-term effects of adjuvant tamoxifen and/or radiotherapy: The South Sweden Breast Cancer Trial. Acta Oncol 31:271-274, 1992
19. Andersson M, Storm HH, Mouridsen HT: Carcinogenic effects of adjuvant tamoxifen treatment and radiotherapy for early breast cancer. Acta Oncol 31:259-263, 1992
20. Fisher B, Costantino JP, Wickerham DL, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388, 1998
21. Swerdlow AJ, Jones ME: Tamoxifen treatment for breast cancer and risk of endometrial cancer: A case-control study. J Natl Cancer Inst 97:375-384, 2005
22. Tonetti DA, Jordan VC: The role of estrogen receptor mutations in tamoxifen-stimulated breast cancer. J Steroid Biochem Mol Biol 62:119-128, 1997
23. Greenland S: Partial and marginal matching in case-control studies, in Moolgavkar SH, Prentice RL (eds): Modern Statistical Methods in Chronic Disease Epidemiology. New York, NY, Wiley, 1986
24. Friedlander Y, Lev Merom D, Kark JD: A comparison of different matching designs in case-control studies: An empirical example using continuous exposures, continuous confounders and incidence of myocardial infarction. Stat Med 12:993-1004, 1993